Skip to content
Search

Latest Stories

Ranvir Shorey to be back in Salman Khan starrer Tiger 3?

Ranvir Shorey to be back in Salman Khan starrer Tiger 3?

By Murtuza Iqbal

Ranvir Shorey played a pivotal role in Ek Tha Tiger, but we didn’t get to see him in the sequel Tiger Zinda Hai. However, now according to a report in Mid-day, Ranvir will be back in the third instalment of the film, Tiger 3.


A source told the tabloid, “While Gavie Chahal, who had a prominent role in Kabir Khan’s Ek Tha Tiger as a section captain of the Inter-Services Intelligence (ISI), transitioned to Tiger Zinda Hai (2017), Ranvir’s character wasn’t extended to the Ali Abbas Zafar-directed venture. When writing the third part, producer Aditya Chopra and writer Jaideep Sahni decided to bring him back as the trusted aide of RAW agent Avinash Singh Rathore, portrayed by Salman. The superstar and Ranvir will begin by filming a comedy sequence with a female actor, following it up with a few high-octane scenes.”

Directed by Maneesh Sharma, Tiger 3 also stars Katrina Kaif in the lead role. While YRF has not yet announced the film officially, it is said that the shooting of the film has already kickstarted.

A few days ago, Katrina was tested positive for Covid-19. However, it is said that the actress’ health won’t be a hurdle in the film’s shoot.

Talking about Ranvir Shorey, the actor was last seen in Lootcase which released on Disney+ Hotstar. The actor also has Santosh Sivan’s Mumbaikar lined up.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less